Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Antoine Moya-PlanaRuth Gabriela Herrera GómezCaroline RossoniLaurent DercleSamy AmmariIsabelle GiraultSéverine RoyJean-Yves ScoazecStephan VagnerFrançois JanotAlexander M M EggermontCaroline RobertPublished in: Cancer immunology, immunotherapy : CII (2019)
In the patients with unresectable and/or metastatic mucosal melanoma, we found ORR and PFS rates comparable to those in patients with cutaneous melanoma, with no significant differences in the types of mucosal surfaces involved. Anti-PD1 therapy has a more favorable benefit-risk ratio than ipilimumab and should be used preferentially.